Anteris Technologies Global Corp. — Capital/Financing Update 2018

Dec 3, 2018

4.12.2018

==> picture [451 x 24] intentionally omitted <==

ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000

Admedus Limited (ASX:AHZ)

DESPATCH OF RIGHTS ISSUE OFFER DOCUMENTS

Admedus Limited ( Admedus ) advises that, by the end of the day, the prospectus together with the personalised entitlement and acceptance forms will be despatched to shareholders who have been determined to be shareholders eligible to participate in the renounceable prorata entitlement offer ( Entitlement Offer ) announced to ASX on Wednesday, 28 November 2018.

The Entitlement Offer opens today, Tuesday, 4 December 2018, and is scheduled to close at 5:00 pm (AEDT) on Thursday, 13 December 2018.

If you are an eligible shareholder and do not receive a copy of the prospectus or have any questions in relation to your entitlement under the Entitlement Offer, please contact the Share Registry, Computershare, via the details listed below.

Shareholders should also note that trading in Admedus’ rights in relation to the Entitlement Offer (ASX: AHZRA) is currently underway and will end on Thursday, 6 December 2018.

ENDS

Admedus Limited

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299 E: info@admedus.com W: admedus.com

==> picture [72 x 72] intentionally omitted <==

Registered Office: Level 9, 301 Coronation Drive, Milton, Queensland 4064

Customer Service:

Brisbane • Minneapolis • Geneva • Singapore

ABN 35 088 221 078

==> picture [451 x 24] intentionally omitted <==

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus Twitter: @Admedus

For more information, please contact:

Share Registry

Computershare Investor Services Pty Ltd Telephone: 1300 557 010 (within Aust) +61 3 9415 4000 (outside Aust) Facsimile: +61 3 9473 2500

Investor Relations

Kyahn Williamson WE Buchan Admedus@we-buchan.com 03 9866 4722

==> picture [24 x 25] intentionally omitted <==